|
注册号: Registration number: |
ChiCTR2200057012 |
|
最近更新日期: Date of Last Refreshed on: |
2023-02-02 21:29:22 |
|
注册时间: Date of Registration: |
2022-02-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
妊娠期糖尿病非药物管理决策支持系统的探索性研究 |
|
Public title: |
An exploratory study on the construction of decision support system for non-pharmaceutical management of gestational diabetes mellitus |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
妊娠期糖尿病非药物管理决策支持系统的探索性研究 |
|
Scientific title: |
An exploratory study on the construction of decision support system for non-pharmaceutical management of gestational diabetes mellitus |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
方园 |
研究负责人: |
周英凤 |
|
Applicant: |
Fang Yuan |
Study leader: |
Zhou Yingfeng |
|
申请注册联系人电话: Applicant telephone: |
+86 15618207720 |
研究负责人电话:
Study leader's |
+86 13671693006 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fy_dyx@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zyingfeng@fudan.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区枫林路305号 |
研究负责人通讯地址: |
上海市徐汇区枫林路305号 |
|
Applicant address: |
305 Fenglin Road, Xuhui District, Shanghai |
Study leader's address: |
305 Fenglin Road, Xuhui District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学护理学院 |
||
|
Applicant's institution: |
School of Nursing, Fudan University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IRB#2018-12-08 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学护理学院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee, School of Nursing, Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2018-12-10 00:00:00 | ||
|
伦理委员会联系人: |
夏海鸥 |
||
|
Contact Name of the ethic committee: |
Xia Haiou |
||
|
伦理委员会联系地址: |
上海市徐汇区枫林路305号 |
||
|
Contact Address of the ethic committee: |
305 Fenglin Road, Xuhui District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
复旦大学护理学院 |
||||||||||||||||||||||
|
Primary sponsor: |
School of Nursing, Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区枫林路305号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
305 Fenglin Road, Xuhui District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China |
||||||||||||||||||||||
|
研究疾病: |
妊娠期糖尿病 |
||||||||||||||||||||||
|
Target disease: |
gestational diabetes mellitus (GDM) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.构建基于证据的妊娠期糖尿病非药物管理决策支持系统; 2.评价妊娠期糖尿病非药物管理决策支持系统的可用性; 3.评价妊娠期糖尿病非药物管理决策支持系统的临床效果 。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To construct an evidence-based decision support system for non-drug management of gestational diabetes mellitus; 2. To evaluate the availability of decision support systems for the nonpharmacological management of gestational diabetes mellitus; 3. To evaluate the clinical effects of a decision support system for the nonpharmacological management of gestational diabetes mellitus. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.需要药物治疗的GDM患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with GDM requiring drug therapy; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-03-01 00:00:00至 To 2023-03-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-03-01 00:00:00 至 To 2023-03-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究者本人在研究开始前通过office办公软件中的excel生成的随机数字表将患者分为干预组和对照组。具体方法为:①在excel中建立函数“=rand()”,并根据样本量,下拉出足够行数的随机数;②在随机数前建立一列编号代表被纳入研究的顺序;③将随机数按数值大小进行排序(扩展排序);④根据随机数的大小分组,前?个数字为A组,后?个数字为B组,在随机数后面的一纵列中标注具体组别为“A组”或“B组”;⑤恢复随机数前被纳入研究顺序编号的正常排序,序列号后对应的“A”、“B”即为本研究随机分组序列。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients were divided into intervention group and control group by a random number table generated by excel in office software before the start of the study. The specific methods are as follows: 1. Create a function "=rand()" in excel, and pull down random numbers with enough rows according to the s |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究对结果测评者实施盲法。复旦大学附属妇产科医院产科产检医护人员及检验科医护人员对研究对象的分组情况不知晓。 |
|
Blinding: |
In this study, the outcome measurers were blinded. The obstetric and obstetric medical staff and laboratory medical staff of the Obstetrics and Gynecology Hospital of Fudan University were not aware of the grouping of the research subjects. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究完成后6个月内公开,网络平台为ResMan临床试验公共管理平台,网址为http://www.medresman.org/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
We will publish our final research results within 6 months after the completion. Public platform is the ResMan clinical trial, and the website is http://www.medresman.org/login.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF、EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF、EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |